[Hyperekplexia -- a treatable neuropediatric disease]

Area of Science:

• Neuroscience
• Genetics
• Pediatrics

Background:

• Hyperekplexia (OMIM 138491) is a rare autosomal dominant neurological disorder.
• It is characterized by an exaggerated startle reflex and neonatal hypertonia.
• Untreated, it poses risks of sudden infant death, apnea, aspiration pneumonia, and injury.

Purpose of the Study:

• To highlight the genetic basis of hyperekplexia.
• To emphasize the importance of early diagnosis and appropriate treatment.
• To discuss the role of genetic counseling in managing the condition.

Main Methods:

• Review of genetic mutations associated with hyperekplexia.
• Discussion of clinical presentation and diagnostic criteria.
• Evaluation of therapeutic interventions.

Main Results:

• Mutations in the alpha1-subunit of the inhibitory glycine receptor (GLRA1) are identified as a cause.
• Clonazepam, a gamma-aminobutyric acid (GABA) receptor agonist, is the primary treatment.
• Early diagnosis facilitates timely and effective management.

Conclusions:

• Prompt diagnosis of hyperekplexia is vital for initiating treatment and preventing severe outcomes.
• Genetic testing and counseling are essential components of patient management.
• Understanding the genetic underpinnings guides therapeutic strategies and family planning.